Keila Barral – Founder & CEO, Cromodata
Keila Barral, founder of Cromodata, brings together a personal journey of resilience and a career in technology to address one of Latin America’s biggest healthcare challenges: fragmented patient data. After…
Address: Via Scuderlando 10 – 37135 Verona,Italy
Tel: +39 045.8222811
Web: http://www.cromsource.com/
CROM is a Contract Research Organisation based in Verona that was launched in 1997. The company also has activities in Poland, Ukraine, Bulgaria, Russia and the Czech Republic.
It offers its customers a broad range of services, from clinical project management and clinical trial monitoring to training seminars.
Keila Barral, founder of Cromodata, brings together a personal journey of resilience and a career in technology to address one of Latin America’s biggest healthcare challenges: fragmented patient data. After…
Martin Prinz, CTO of Croma-Pharma, a family-owned Austrian aesthetic dermatology company, discusses the evolution of the company over the years and their specialist, ever-expanding portfolio. Additionally, he documents the role…
Arturo Rodríguez Jacob, CEO at Infinite Clinical Research (ICR) and president of the national association of CROs (ACROM), explains what make Mexico the regional clinical research hub and showcases how…
You are specialised in Cardiology at Padua University, in Tropical Medicine and Hygiene at London University and in Pharmacology at Modena University, in Communication at Bocconi University in Milan, and…
Grunenthal-Formenti relies on Formenti’s 60 years experience in Italy and is the result of the merger of both the German and Italian entities in 96. How would you describe the…
Having led a 26 years long career in Pfizer, you have been involved in a number of different countries including leading markets such as the US and Japan, but also…
You have worked in other countries such as the UK and the US with very large and significant pharmaceutical industries. What would you say is particular about the Italian pharmaceutical…
Since 1982, CNR has been the Italian public body which most contributed to the creation of inventions and innovations. What have been the main strategies behind such a success in…
Over more than 25 years, PAREXEL has expanded its global footprint through a combination of organic growth, alliances, and acquisitions. What was the rationale behind entering Italy in 1995 and…
Roche Italy is one of the companies which went through the most significant re-organization process in the country in the past three years- with important changes in both its marketing…
When you were appointed General Director of the Agenzia Italiana del Farmaco (AIFA) in 2007, the dedicated Investigation Commission highlighted the need for an in-depth reorganization of the Agency in…
When you became President of Sankyo Pharma Italy in 2003 one of your objectives was to maximize sales of the existing portfolio- and the company’s sales have impressively tripled in…
“The ball is in the hands of the government,” according to Giorgio Foresti, general manager of Ratiopharm. “Once aware of the opportunities created by generics, politicians will have to make…
The pharmaceutical industry arose from science – and so did Italy’s knowledge based economy. Building on a reputation for innovation carved in the 15th century, when Leonardo Da Vinci, Michelangelo,…
Petrone group was created in 1965, based on your parents’ Carmine and Fernanda’s entrepreneurial spirit. They survived through times of challenges for Italian groups and maintained their independence. In your…
Scharper’s history in the Italian market begins in 1958, but the company as we see it today was really created in the mid nineties, when you founded La Farmochimica Italiana…
See our Cookie Privacy Policy Here
